Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.

Author: Vudosho Nikotaxe
Country: Sri Lanka
Language: English (Spanish)
Genre: Science
Published (Last): 11 January 2017
Pages: 378
PDF File Size: 7.13 Mb
ePub File Size: 2.21 Mb
ISBN: 668-8-53545-478-9
Downloads: 63766
Price: Free* [*Free Regsitration Required]
Uploader: Mikashicage

Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Cancer AND drug name. Pneumonia AND sponsor name. How to search [pdf].

Medicinas para Quimioterapia – Nombres de Medicina

For these items you should use the filters and not add them to your search terms in the text field. Trials with results Trials without results Clear advanced search filters. Review by the Competent Authority or Ethics Committee in the country concerned. EU Clinical Trials Register. Both Female Only Male Only. IMP with orphan designation in the indication. Trials with results Trials without results.

Clear advanced search filters.

Date on which this record was first entered in the EudraCT database:. Title of the trial for lay people, in easily understood, i. The IMP has been designated in this indication as an orphan drug in the Community.


Committee on Advanced therapies CAT has efects a classification for this product. Combination product that includes a device, but does not involve an Advanced Therapy.

Relapsed or Refractory Acute Lymphoblastic Leukemia. A group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells. Phase 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment of children with relapsed or refractory acute lymphoblastic leukemia ALL -To determine the maximum tolerated dose MTD of carfilzomib p-asparaginasa combination with induction chemotherapy.

Age 18 years or younger at the time of study treatment initiation. Subjects must have fully recovered from the efeectos toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment. Subjects must have a serum creatinine level that is? Adequate liver function, defined as both of the following: Karnofsky or Lansky scores?

Known allergy to any of the drugs used in the study. Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible.

Known allergy to Captisol a cyclodextrin derivative eefectos to solubilize carfilzomib; for a complete listing of Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc. Active treatment for graft-versus-host disease 6. Positive culture for bacteria or fungus within 14 days of the initiation of therapy 7.


For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be approved by the Onyx study medical monitor. Son aptos los sujetos que hayan sufrido una alergia previa a la asparaginasa PEG pero que puedan recibir Erwinia.

Asparaginasa inyectable

Restricciones de tratamientos previos: Los sujetos deben haber finalizado todo tipo de inmunoterapia activa p. Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy? The trial involves single site in the Member State concerned.

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial. Subjects are under 18 years old. Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment l-asparainasa that condition.